DARZALEX 400mg/20ml Infusion/Concentrate for Solution for

What is DARZALEX 400mg/20ml

DARZALEX 400mg/20ml is a concentrate for infusion containing Daratumumab, a monoclonal antibody used in the treatment of multiple myeloma. Daratumumab targets the CD38 protein on myeloma cells, leading to their destruction by the immune system.

This intravenous formulation is used either as monotherapy or in combination with other cancer treatments, particularly for patients who have relapsed or are refractory to prior treatments. It plays a significant role in the treatment of multiple myeloma.

How to use DARZALEX 400mg/20ml

DARZALEX 400mg/20ml is administered intravenously. The usage instructions are as follows:

• Administration Route: Intravenous infusion administered by a healthcare professional.
• Infusion Schedule: Infusions are typically given weekly during the initial treatment phase, followed by less frequent infusions (e.g., biweekly or monthly) during the maintenance phase.
• Premedication: Patients are usually premedicated with corticosteroids, antihistamines, and antipyretics to reduce the risk of infusion-related reactions.

Close monitoring during and after the infusion is required to manage potential side effects.

Mode of Action DARZALEX 400mg/20ml

DARZALEX 400mg/20ml works by targeting the CD38 protein found on the surface of multiple myeloma cells. By binding to CD38, Daratumumab triggers immune responses that result in the destruction of these cancer cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

• Mechanism of Action: Daratumumab binds to CD38, facilitating immune-mediated destruction of myeloma cells.
• Indications: DARZALEX is used for treating multiple myeloma, either alone or in combination with other therapies, particularly in patients who are relapsed or refractory to prior treatments.

This intravenous infusion is an essential option for patients with advanced stages of multiple myeloma.

DARZALEX 400mg/20ml Interactions DARZALEX 400mg/20ml

Potential drug interactions to consider before using DARZALEX 400mg/20ml:

• Immunosuppressants: Combining Daratumumab with other immunosuppressive agents may increase the risk of infections.
• Live Vaccines: Live vaccines should be avoided during treatment, as Daratumumab may weaken the immune response.
• Blood Transfusion: Daratumumab may interfere with blood typing and cross-matching, so healthcare providers should be informed of its use before a transfusion.

Consult with your healthcare provider about current medications to avoid potential interactions with DARZALEX 400mg/20ml.

Dosage of DARZALEX 400mg/20ml

The dosing schedule for DARZALEX 400mg/20ml typically follows a phased approach:

• Initial Dosing: Weekly infusions for the first 4 to 8 weeks, depending on the patient's response and specific treatment regimen.
• Maintenance Dosing: Infusions may be given biweekly or monthly after the initial treatment phase.
• Consultation: Always follow the prescribed dosing schedule as recommended by your healthcare provider.

Regular monitoring and adherence to the dosing regimen are critical for the effective management of multiple myeloma.

Possible side effects of DARZALEX 400mg/20ml

Common side effects of DARZALEX 400mg/20ml may include:

• Infusion-related reactions (e.g., fever, chills, difficulty breathing)
• Fatigue
• Upper respiratory infections
• Nausea
• Low blood cell counts (e.g., neutropenia, anemia)

Seek immediate medical attention if severe side effects, such as severe allergic reactions or difficulty breathing, occur.

DARZALEX 400mg/20ml Contraindications DARZALEX 400mg/20ml

Contraindications to consider before starting treatment with DARZALEX 400mg/20ml:

• Known hypersensitivity to Daratumumab or any of its components.
• Pregnancy and breastfeeding: DARZALEX may pose risks to the fetus or newborn, and its use should be avoided during pregnancy unless absolutely necessary.
• Active infections: Treat any active infections before initiating Daratumumab therapy.

Discuss your medical history with your healthcare provider to ensure safe administration of DARZALEX 400mg/20ml.

Storage of DARZALEX 400mg/20ml

Storage recommendations for DARZALEX 400mg/20ml include:

• Store the vials in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Do not freeze or shake the vials.
• Prepared infusions should be used within the timeframe specified by the healthcare provider.

Proper storage ensures the safety and efficacy of DARZALEX 400mg/20ml during administration.